• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Editorial: Raising the bar: advancing therapeutic strategies for fighting communicable and noncommunicable diseases.

作者信息

Tanoto Dariel Wilbert, Lee Jia Wen, Chong Yee Kien, Lani Rafidah, Hassandarvish Pouya, Oo Adrian

机构信息

Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University Health System, National University of Singapore, Singapore, Singapore.

Retroviral Immunology, The Francis Crick Institute and Department of Medicine, Faculty of Medicine, Imperial College London, London, United Kingdom.

出版信息

Front Pharmacol. 2024 Sep 17;15:1486889. doi: 10.3389/fphar.2024.1486889. eCollection 2024.

DOI:10.3389/fphar.2024.1486889
PMID:39355772
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11442419/
Abstract
摘要

相似文献

1
Editorial: Raising the bar: advancing therapeutic strategies for fighting communicable and noncommunicable diseases.社论：提高标准：推进抗击传染病和非传染病的治疗策略
Front Pharmacol. 2024 Sep 17;15:1486889. doi: 10.3389/fphar.2024.1486889. eCollection 2024.
2
Synergies between Communicable and Noncommunicable Disease Programs to Enhance Global Health Security.传染性和非传染性疾病防控项目协同增效，增强全球卫生安全。
Emerg Infect Dis. 2017 Dec;23(13):S40-6. doi: 10.3201/eid2313.170581.
3
Editorial: Non-communicable diseases; sexual reproductive issues; infectious diseases and health systems challenges.社论：非传染性疾病；性与生殖问题；传染病及卫生系统挑战
Afr Health Sci. 2022 Dec;22(4):i-v. doi: 10.4314/ahs.v22i4.1.
4
Editorial: Sexual dimorphism of the immune inflammatory response in infectious and non-infectious diseases, volume II.社论：感染性和非感染性疾病中免疫炎症反应的性别差异，第二卷。
Front Immunol. 2023 Nov 30;14:1341365. doi: 10.3389/fimmu.2023.1341365. eCollection 2023.
5
Communicable or noncommunicable diseases? Building strong primary health care systems to address double burden of disease in India.传染病还是非传染病？建立强大的初级卫生保健系统以应对印度的双重疾病负担。
J Family Med Prim Care. 2019 Feb;8(2):326-329. doi: 10.4103/jfmpc.jfmpc_67_19.
6
Non-communicable disease, sociodemographic factors, and risk of death from infection: a UK Biobank observational cohort study.非传染性疾病、社会人口因素与感染死亡风险：英国生物银行观察性队列研究。
Lancet Infect Dis. 2021 Aug;21(8):1184-1191. doi: 10.1016/S1473-3099(20)30978-6. Epub 2021 Mar 1.
7
Fighting non-communicable diseases in the COVID-19 era: a catch 22?在新冠疫情时代抗击非传染性疾病：是一种两难困境吗？
Acta Cardiol. 2022 Jun;77(4):366-367. doi: 10.1080/00015385.2021.1887587. Epub 2021 Mar 8.
8
Burden of non-communicable diseases from infectious causes in 2017: a modelling study.2017 年由传染性病因导致的非传染性疾病负担：一项建模研究。
Lancet Glob Health. 2020 Dec;8(12):e1489-e1498. doi: 10.1016/S2214-109X(20)30358-2. Epub 2020 Oct 21.
9
Double burden of noncommunicable and infectious diseases in developing countries.发展中国家的非传染性疾病和传染病双重负担。
Science. 2012 Sep 21;337(6101):1499-501. doi: 10.1126/science.1223466.
10
Evolution of non-communicable disease prevention and control in China.中国非传染性疾病防控的演变。
Glob Health Promot. 2019 Dec;26(4):90-95. doi: 10.1177/1757975917739621. Epub 2017 Dec 11.

本文引用的文献

1
Biological synthesis of ursodeoxycholic acid.熊去氧胆酸的生物合成
Front Microbiol. 2023 Feb 24;14:1140662. doi: 10.3389/fmicb.2023.1140662. eCollection 2023.
2
Updates on Group B Infection in the Field of Obstetrics and Gynecology.妇产科学领域中B族感染的最新进展
Microorganisms. 2022 Dec 2;10(12):2398. doi: 10.3390/microorganisms10122398.
3
FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2.法尼醇 X 受体（FXR）抑制可能通过降低 ACE2 来预防严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）感染。
Nature. 2023 Mar;615(7950):134-142. doi: 10.1038/s41586-022-05594-0. Epub 2022 Dec 5.
4
The role of antiviral treatment in the COVID-19 pandemic.抗病毒治疗在新冠疫情中的作用。
Lancet Respir Med. 2022 Feb;10(2):e18. doi: 10.1016/S2213-2600(22)00011-X. Epub 2022 Jan 13.
5
Early outcome and safety of bedaquiline-containing regimens for treatment of MDR- and XDR-TB in China: a multicentre study.中国含贝达喹啉方案治疗耐多药和广泛耐药结核病的早期结局和安全性：一项多中心研究。
Clin Microbiol Infect. 2021 Apr;27(4):597-602. doi: 10.1016/j.cmi.2020.06.004. Epub 2020 Jun 15.
6
In vitro antimicrobial combination testing of and evolution of resistance to the first-in-class spiropyrimidinetrione zoliflodacin combined with six therapeutically relevant antimicrobials for Neisseria gonorrhoeae.淋病奈瑟菌首创新药螺吡喃嘧啶酮与六种治疗相关抗菌药物联合的体外抗菌组合试验及耐药演变。
J Antimicrob Chemother. 2019 Dec 1;74(12):3521-3529. doi: 10.1093/jac/dkz376.
7
Cardiac safety of bedaquiline: a systematic and critical analysis of the evidence.贝达喹啉的心脏安全性：证据的系统与批判性分析
Eur Respir J. 2017 Nov 16;50(5). doi: 10.1183/13993003.01462-2017. Print 2017 Nov.
8
The Prevention of Early-Onset Neonatal Group B Streptococcal Disease.早发型新生儿B族链球菌病的预防
J Obstet Gynaecol Can. 2016 Dec;38(12S):S326-S335. doi: 10.1016/j.jogc.2016.09.042. Epub 2017 Jan 4.
9
Vancomycin therapy in critically ill patients on continuous renal replacement therapy; are we doing enough?接受持续肾脏替代治疗的重症患者的万古霉素治疗；我们做得够吗？
Saudi Pharm J. 2015 Jul;23(3):327-9. doi: 10.1016/j.jsps.2014.08.005. Epub 2014 Sep 7.
10
Bedaquiline: a novel diarylquinoline for multidrug-resistant tuberculosis.贝达喹啉：一种用于耐多药结核病的新型二芳基喹啉。
Ann Pharmacother. 2014 Jan;48(1):107-15. doi: 10.1177/1060028013504087. Epub 2013 Nov 1.